| pubmed-article:11264451 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11264451 | lifeskim:mentions | umls-concept:C0031332 | lld:lifeskim |
| pubmed-article:11264451 | lifeskim:mentions | umls-concept:C0003765 | lld:lifeskim |
| pubmed-article:11264451 | pubmed:dateCreated | 2001-3-26 | lld:pubmed |
| pubmed-article:11264451 | pubmed:abstractText | L-Arginine (2-amino-5-guanidinovaleric acid) is the precursor of nitric oxide, an endogenous messenger molecule involved in a variety of endothelium-mediated physiological effects in the vascular system. Acute and chronic administration of L-arginine has been shown to improve endothelial function in animal models of hypercholesterolemia and atherosclerosis. L-Arginine also improves endothelium-dependent vasodilation in humans with hypercholesterolemia and atherosclerosis. The responsiveness to L-arginine depends on the specific cardiovascular disease studied, the vessel segment, and morphology of the artery. The pharmacokinetics of L-arginine have recently been investigated. Side effects are rare and mostly mild and dose dependent. The mechanism of action of L-arginine may involve nitric oxide synthase substrate provision, especially in patients with elevated levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine. Endocrine effects and unspecific reactions may contribute to L-arginine-induced vasodilation after higher doses. Several long-term studies have been performed that show that chronic oral administration of L-arginine or intermittent infusion therapy with L-arginine can improve clinical symptoms of cardiovascular disease in man. | lld:pubmed |
| pubmed-article:11264451 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11264451 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11264451 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11264451 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11264451 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11264451 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11264451 | pubmed:issn | 0362-1642 | lld:pubmed |
| pubmed-article:11264451 | pubmed:author | pubmed-author:Bode-BögerS... | lld:pubmed |
| pubmed-article:11264451 | pubmed:author | pubmed-author:BögerR HRH | lld:pubmed |
| pubmed-article:11264451 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11264451 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:11264451 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11264451 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11264451 | pubmed:pagination | 79-99 | lld:pubmed |
| pubmed-article:11264451 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11264451 | pubmed:meshHeading | pubmed-meshheading:11264451... | lld:pubmed |
| pubmed-article:11264451 | pubmed:meshHeading | pubmed-meshheading:11264451... | lld:pubmed |
| pubmed-article:11264451 | pubmed:meshHeading | pubmed-meshheading:11264451... | lld:pubmed |
| pubmed-article:11264451 | pubmed:meshHeading | pubmed-meshheading:11264451... | lld:pubmed |
| pubmed-article:11264451 | pubmed:meshHeading | pubmed-meshheading:11264451... | lld:pubmed |
| pubmed-article:11264451 | pubmed:meshHeading | pubmed-meshheading:11264451... | lld:pubmed |
| pubmed-article:11264451 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11264451 | pubmed:articleTitle | The clinical pharmacology of L-arginine. | lld:pubmed |
| pubmed-article:11264451 | pubmed:affiliation | Institute of Clinical Pharmacology, Hannover Medical School, D-30623 Hannover, Germany. | lld:pubmed |
| pubmed-article:11264451 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11264451 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:11264451 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11264451 | lld:pubmed |
